424 related articles for article (PubMed ID: 28056941)
1. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
3. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
[TBL] [Abstract][Full Text] [Related]
4. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
5. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
7. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK
J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.
de Martino M; Pantuck AJ; Hofbauer S; Waldert M; Shariat SF; Belldegrun AS; Klatte T
J Urol; 2013 Dec; 190(6):1999-2004. PubMed ID: 23831313
[TBL] [Abstract][Full Text] [Related]
9. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
11. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
13. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
[TBL] [Abstract][Full Text] [Related]
14. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H
BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491
[TBL] [Abstract][Full Text] [Related]
15. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
20. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]